Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.
M. Lynn Crismon, Pharm.D. has been named the recipient of the 2021 Distinguished Leadership Award from the American Society of Health-System Pharmacists Board of Directors. The award is one of the highest honors in the pharmacy profession.
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.
Neuroscience graduate student Cherish Taylor took home the top prize in the Graduate School’s Three Minute Thesis competition. Taylor is a graduate student in the lab of Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. in the College of Pharmacy’s Division of Pharmacology and Toxicology.
It is with great sadness that we announce the passing of Edward (Ted) Mills, Ph.D., associate professor in the Division of Pharmacology and Toxicology and Bergen Brunswig Corporation Centennial Fellow.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.